Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial


Cite item

Full Text

Abstract

The article deals with the results of the administration of new cytostatic - eribulin (Halaven). In EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) phase III clinical study, Halaven had been administrated to 6 patients (between 6 and 35 cycles), at that, partial tumor regression was observed in 3 patients and other 3 patients achieved stabilization. Median progression-free survival (PFS) was 15,3 months and median duration of response (DOR) was 13 months in eribulin group, in group of treatment of physician's choice - median PFS was 5,3 and median DOR was 3,3 months. This article demonstrates 3 clinical cases. The authors concluded that eribulin showed high effectiveness and meaningful improvement in overall survival, maintaining the high quality of life.

About the authors

F Sh Ahmetzanov

ГБОУ ВПО Казанский государственный медицинский университет Минздрава России

проф., ректор, зав. каф. онкологии, лучевой диагностики и лучевой терапии

F F Ahmetzanova

ГБОУ ВПО Казанский государственный медицинский университет Минздрава России

ассистент каф. онкологии, лучевой диагностики и лучевой терапии

References

  1. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2009 г. Вестн. Российского онкологического научного центра им. Н.Н.Блохина РАМН. 2011; 22 (3; Прил. 1): 54-92.
  2. Состояние онкологической помощи населению России в 2013 г. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: ФГБУ МНИОИ им. П.А.Герцена, 2014.
  3. Morris P.G. Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs 2010; 21 (10): 885-9.
  4. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow - up. Ann Oncol 2012; 23 (Suppl. 7): 11-9.
  5. NCCN Guidelines Version 3.2014, Invasive Breast Cancer BINV-20. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
  6. Gennari A, Conte P.F, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104 (I.8.): 1742-50.
  7. Hirata Y, Uemura D. Halichondrins antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986; 58: 701-10.
  8. Kuznetsov G et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760-6.
  9. Towle M.J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61: 1013-21.
  10. Jordan M.A et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4: 1086-95.
  11. Okouneva T et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008; 7: 2003-11.
  12. Smith J.A et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010; 49: 1331-7.
  13. Towle M.J et al. Eribulin induces irreversible mitotic blockade: implications of cell - based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71: 496-505.
  14. Goel S et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009; 15: 4207-12.
  15. Tan A.R et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 4213-9.
  16. Synold T.W et al. A Phase I pharmacokinetic and target validation study of the novel anti - tubulin agent E7389: A California Cancer Consortium trial. J Clin Oncol 2005; 23 (Suppl. 16): 3036.
  17. Minami H et al. A Phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer 2008; 6 (Suppl.): 140 (Abstract 446).
  18. Vahdat L.T et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxanes. J Clin Oncol 2009; 27: 2954-61.
  19. Cortes J et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28: 3922-8.
  20. Twelves C, Loesch D et al. Updated survival analysis of a Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX, USA; p. 6-14-8.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies